Dr. Ruham Alshiekh Nasany, MD

Dr. Alshiekh Nasany practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Alshiekh Nasany's NPI, 1649699570, was assigned on April 8, 2014. Dr. Alshiekh Nasany graduated from University of Aleppo Faculty of Medicine in 2010. Dr. Alshiekh Nasany holds Florida license ME159131.

Dr. Alshiekh Nasany's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Alshiekh Nasany's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Alshiekh Nasany to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alshiekh Nasany practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Alshiekh Nasany's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Alshiekh Nasany is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Alshiekh Nasany's licenses on file in 2 states: Florida and New York.

CMS data shows 178 Medicare services from Dr. Alshiekh Nasany across 3 procedure codes in 2024, for 64 Medicare patients. Medicare paid $20,491 for them.

CMS counts 64 Medicare patients who saw Dr. Alshiekh Nasany in 2024. The largest group is 65 to 74, with 36 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alshiekh Nasany's median patient age at 67, with 47% women.

In 2024, Dr. Alshiekh Nasany wrote 69 Medicare Part D claims for 21 patients. 93% of them were for generic drugs. CMS names the drug for 44 of them, across 3 drugs with 11 or more claims each, at $6,740 in total drug cost. In 2023, CMS named 79 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Alshiekh Nasany for performance year 2024, reported as part of a group. Dr. Alshiekh Nasany accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Alshiekh Nasany as offering telehealth.

Dmand AI links 3 papers to Dr. Alshiekh Nasany, published from 2021 to 2025. The most frequent topics are Brain Neoplasms. Dr. Alshiekh Nasany's most frequent co-authors are Macarena Ines De La Fuente, MD, David H H. Abramson, MD and Jay S. Chandar, MD.

Dmand AI links Dr. Alshiekh Nasany to 3 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Glioblastoma, Astrocytoma and Brain Neoplasms.

CMS Open Payments shows 3 general payments to Dr. Alshiekh Nasany from 3 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 100% of the total. Kestra Medical Technology Services, Inc. paid the most, $157.

Dr. Alshiekh Nasany graduated from University of Aleppo Faculty of Medicine in 2010.

Dr. Alshiekh Nasany is in network with 11 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.